Triple

Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).

Phrase: Directive 2012/26/EU | Statement: [Directive 2001/83/EC, amendedBy, Directive 2012/26/EU]

Target entity: Directive 2012/26/EU
Context triple: [Directive 2001/83/EC, amendedBy, Directive 2012/26/EU]

• A. Directive 2013/37/EU
  Directive 2013/37/EU is a European Union law that updated and expanded the rules on the re-use of public sector information to promote transparency, innovation, and economic activity across the EU.
• B. Directive 2010/53/EU
  Directive 2010/53/EU is a European Union law that sets common standards for the quality and safety of human organs intended for transplantation across EU member states.
• C. Directive 2014/65/EU
  Directive 2014/65/EU is a key European Union legislative act that overhauls and strengthens the regulatory framework for investment services and financial markets, commonly known as MiFID II.
• D. Directive 2013/36/EU
  Directive 2013/36/EU is a key European Union legislative act that sets prudential rules and supervisory standards for credit institutions and investment firms as part of the EU’s post-crisis banking regulation framework.
• E. Directive 2014/34/EU
  Directive 2014/34/EU is a European Union law that harmonizes safety requirements for equipment and protective systems intended for use in potentially explosive atmospheres (ATEX) within the EU internal market.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Target entity: Directive 2012/26/EU
Target entity description: Directive 2012/26/EU is a European Union legislative act that strengthened pharmacovigilance rules and safety monitoring for medicinal products for human use by updating the EU’s medicines regulatory framework.

• A. Directive 2013/37/EU
  Directive 2013/37/EU is a European Union law that updated and expanded the rules on the re-use of public sector information to promote transparency, innovation, and economic activity across the EU.
• B. Directive 2010/53/EU
  Directive 2010/53/EU is a European Union law that sets common standards for the quality and safety of human organs intended for transplantation across EU member states.
• C. Directive 2014/65/EU
  Directive 2014/65/EU is a key European Union legislative act that overhauls and strengthens the regulatory framework for investment services and financial markets, commonly known as MiFID II.
• D. Directive 2013/36/EU
  Directive 2013/36/EU is a key European Union legislative act that sets prudential rules and supervisory standards for credit institutions and investment firms as part of the EU’s post-crisis banking regulation framework.
• E. Directive 2014/34/EU
  Directive 2014/34/EU is a European Union law that harmonizes safety requirements for equipment and protective systems intended for use in potentially explosive atmospheres (ATEX) within the EU internal market.
• F. None of above. chosen